Matrix metalloproteinases expression in lentigo maligna ∕lentigo maligna melanoma - a review of the literature and personal experience.

Matrix metalloproteinases expression in lentigo maligna∕lentigo maligna melanoma - a review of the literature and personal experience. Rom J Morphol Embryol. 2019;60(4):1091-1095 Authors: Brînzea A, Nedelcu RI, Ion DA, Turcu G, Antohe M, Hodorogea A, Călinescu A, Pirici D, Popescu R, Popescu CM, Popp CG, Nichita L, Cioplea MD, Cordun M, Zurac SA Abstract Cutaneous melanoma is the most aggressive type of skin cancer, with high invasive potential. Lentigo maligna melanoma (LMM) is a relatively rare type, accounting for about 10% of all melanomas, while the most common subtype of melanoma on the face, typically on chronically sun-exposed skin of elderly people. Its in situ stage is lentigo maligna (LM). During the process of transformation from LM to LMM, tumor cells secrete or induce the release from neighboring cells of large amounts of matrix metalloproteinases (MMPs) that degrade the extracellular matrix. Some MMPs, as MMP3 and MMP9 expressed melanoma cells is associated with statistical significance in both in vitro and in vivo studies, with an invasive phenotype. Unfortunately, there is scarce data published about MMPs expression in LM∕LMM, as majority of research on melanoma refer to superficial spreading and nodular melanoma. Our personal, unpublished yet fully data is an attempt to complete a specific panel of immunohistochemical markers that could explain the slow growing rate of LMM. PMID: 32239083 [PubMed - in process]
Source: Romanian Journal of Morphology and Embryology - Category: General Medicine Tags: Rom J Morphol Embryol Source Type: research

Related Links:

Authors: Pala P, Bergler-Czop BS, Gwiżdż JM Abstract Telemedicine may be described as a modern technology supporting health care at a distance. Dermatology, as a visually-dependent specialty, is particularly suited for this kind of the health care model. This has been proven in a number of recent studies, which emphasized feasibility and reliability of teledermatology. Many patients in the world still do not have access to appropriate dermatological care, while skin cancers morbidity is on an upward trend. Technological development has enabled clinicians to care for diverse patient populations in need of skin exp...
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research
The objective of this study is to investigate the risk of non-melanoma skin cancer in patients with connective tissue disease and to assess the impact of immunosuppressive therapy on this risk. This is a retrospective case control cohort study of 8281 patients with connective tissue disease (systemic lupus erythematosus, Sjogren’s disease and scleroderma) and 8281 age, race, and gender matched controls followed for a 5-year period between 2002-2012, who obtained their care from a large integrated multispecialty group practice in Northern California. The odds ratio for developing squamous cell skin cancer among patien...
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research
AbstractNon-melanoma skin cancer (NMSC), despite its low mortality, can impose a significant psychological burden on patients. The aim of the present study is to examine the evolution of the quality of life (QOL) in patients with cervicofacial NMSC during treatment. This prospective cohort study was conducted to a group of patients with cervicofacial NMSC, confirmed by skin biopsy. These patients completed the Skin Cancer Index questionnaire at the time of diagnosis and at 1  week, 1 month and 6 months after treatment began. Data for these patients’ demographic characteristics and variables related to ...
Source: Journal of Cancer Education - Category: Cancer & Oncology Source Type: research
oit Recently, Kato et al. reported recurrent activating mutations in the SET domain of histone methyltransferase G9a, driving an oncogenic cascade in melanoma. The authors also reported correlations between G9a expression and the regulation of the canonical WNT pathway. Although we could not observe such mutations in human colorectal adenocarcinoma, newly reported findings are of high relevance to colorectal cancer, as WNT target gene signatures were closely associated with G9a expression. Here, we put into perspective such new results on G9a expression in colorectal cancers and the potential relationship with tumor he...
Source: Genes - Category: Genetics & Stem Cells Authors: Tags: Perspective Source Type: research
Conclusion: ICIs demonstrated efficacy and safety in Taiwanese patients with melanoma. Combination treatment showed the greatest efficacy, but this was also accompanied by greater toxicity among the four regimens. In addition, we identified important prognostic factors, such as liver metastases, performance status, and tumor response, for both PFS and OS. These findings could provide physicians with more information to justify clinical outcomes observed in Asian patients with advanced melanoma.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
SummaryThe management of head and neck tumors is challenging and requires a  multidisciplinary approach. Besides the common histology of squamous cell cancer, other histologies like adenoid cystic carcinoma, mucosal melanoma, and adenocarcinoma are often present. These tumors are radioresistant and need high radiation doses. Photon beam therapy is often limited by the norm al tissue tolerance, and particle therapy using protons or carbon ions is a valuable treatment option. Due to their dosimetric advantages, protons enable deposition of high tumor doses, while optimally sparing the surrounding tissue. Carbon ion...
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
The discovery of immune checkpoint inhibitors (ICIs), which include anti-programmed cell death protein-1 (PD-1), its ligand (PD-L1) and anti-cytotoxic T cell lymphocyte-associated protein-4 (CTLA-4), has transformed the field of oncology, with indications continuing to increase. For example, anti-PD1 and anti-CTLA-4 ICIs, which include nivolumab, pembrolizumab and ipilimumab, are US Food and Drug Administration/European Medicines Agency approved for a variety of cancers, such as melanoma and non-small cell lung carcinoma (NSCLC) [1]. Considered the Achilles' heel of ICIs, however, are immune-related adverse events (irAEs) ...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Original Articles: Research letters Source Type: research
Discussion[99mTc]-tilmanocept SPECT/CT resulted in an excellent choice for preoperative lymphatic mapping and presented an optimal biodistribution with a rapid injection-site clearance and persistent SLN retention that could lead to improved accuracy of sentinel node identification in selected cases of melanoma, oral and breast cancer.
Source: Clinical and Translational Imaging - Category: Radiology Source Type: research
Queirolo Rosaria Gangemi Uveal melanoma (UM) is a rare tumor of the eye that leads to deadly metastases in about half of the patients. ADAM10 correlates with c-Met expression in UM and high levels of both molecules are related to the development of metastases. MiR122 and miR144 modulate ADAM10 and c-Met expression in different settings. We hypothesized a potential onco-suppressive role for miR122 and miR144 through modulation of ADAM10 and c-Met in UM. We analyzed the UM Cancer Genome Atlas data portal (TCGA) dataset, two other cohorts of primary tumors and five human UM cell lines for miR122 and miR144 expression b...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Authors: Zamanian-Daryoush M, Lindner DJ, Buffa J, Gopalan B, Na J, Hazen SL, DiDonato JA Abstract Previously, we reported apolipoprotein A-I (apoA-I), the major protein component of high-density lipoprotein (HDL), has potent anti-melanoma activity. We used DNA microarray and bioinformatics to interrogate gene expression profiles of tumors from apoA-I expressing (A-I Tg+/-) versus apoA-I-null (A-I KO) animals to gain insights into mechanisms of apoA-I tumor protection. Differential expression analyses of 11 distinct tumors per group with> 1.2-fold cut-off and a false discovery rate adjusted p
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Cancer | Cancer & Oncology | General Medicine | Melanoma | Romania Health | Skin | Skin Cancer | Statistics | Study